| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d126d2fdd031801141588af1b09eff24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb141b396e502bfce986c491d722e401 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-787 |
| filingDate |
2021-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feab1b8ce9009ebf19e39654100e9812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db16f415279674684de3e9bf8ebade7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_375a531445e1deeca7179e1ae8ee823b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74837926f58484d4c20977221b55991b |
| publicationDate |
2021-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021146749-A1 |
| titleOfInvention |
Toll-like receptor agonist formulations and methods of use |
| abstract |
Aspects of the disclosure relate to nanoparticle formulations and methods for generating nanoparticles. Embodiments include nanoparticles comprising an amphiphile and a polymer co-assembly agent. In some cases, polymers for use in therapeutic delivery are described. In some embodiments, the disclosed methods and compositions involve TLR agonists and formulations thereof capable of activating an immune response. Certain aspects relate to nanoparticles comprising linked TLR agonists for use in immunotherapy. |
| priorityDate |
2020-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |